Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators

Stock News

Sep 06

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH) announced that it has recently received the official "Acceptance Notification" issued by China's National Medical Products Administration (NMPA).

The company's new drug application for the injection of recombinant human thyrotropin beta (formerly known as recombinant human thyroid-stimulating hormone injection, under the brand name Zesuning®) has been officially accepted for review.

The newly accepted indication is specifically for the treatment of patients with differentiated thyroid cancer without distant metastasis, aimed at facilitating the clearance of residual thyroid tissue in conjunction with radioactive iodine (131I) therapy following a total or near-total thyroidectomy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1108768389"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108768389\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108768389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-06 15:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108768389","market":"other","top_or_hot":-1,"title":"Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators","media":"Stock News","content":"<p><b>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH)</b> announced that it has recently received the official \"Acceptance Notification\" issued by China's National Medical Products Administration (NMPA).<br><br>The company's new drug application for the injection of recombinant human thyrotropin beta (formerly known as recombinant human thyroid-stimulating hormone injection, under the brand name Zesuning®) has been officially accepted for review.<br><br>The newly accepted indication is specifically for the treatment of patients with differentiated thyroid cancer without distant metastasis, aimed at facilitating the clearance of residual thyroid tissue in conjunction with radioactive iodine (131I) therapy following a total or near-total thyroidectomy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-06 15:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH)</b> announced that it has recently received the official \"Acceptance Notification\" issued by China's National Medical Products Administration (NMPA).<br><br>The company's new drug application for the injection of recombinant human thyrotropin beta (formerly known as recombinant human thyroid-stimulating hormone injection, under the brand name Zesuning®) has been officially accepted for review.<br><br>The newly accepted indication is specifically for the treatment of patients with differentiated thyroid cancer without distant metastasis, aimed at facilitating the clearance of residual thyroid tissue in conjunction with radioactive iodine (131I) therapy following a total or near-total thyroidectomy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1108768389","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108768389","pubTimestamp":1788680316,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH) announced that it has recently received the official \"Acceptance Notification\" issued by China's National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药-U","01477":"欧康维视生物-B","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"苏州泽尔根甲状腺癌治疗新药申请获监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"IPOS":1,"01477":1},"content_text":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH) announced that it has recently received the official \"Acceptance Notification\" issued by China's National Medical Products Administration (NMPA).The company's new drug application for the injection of recombinant human thyrotropin beta (formerly known as recombinant human thyroid-stimulating hormone injection, under the brand name Zesuning®) has been officially accepted for review.The newly accepted indication is specifically for the treatment of patients with differentiated thyroid cancer without distant metastasis, aimed at facilitating the clearance of residual thyroid tissue in conjunction with radioactive iodine (131I) therapy following a total or near-total thyroidectomy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}